Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.

Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Abstract Text:

    thomas j f nielandThomas J F Nieland,jared t shawJared T Shaw,firoz a jaipuriFiroz A Jaipuri,zoltan maligaZoltan Maliga,jay l duffnerJay L Duffner,angela n koehlerAngela N Koehler,monty kriegerMonty Krieger,

    Treatment of atherosclerotic disease often focuses on reducing plasma LDL-cholesterol or increasing plasma HDL-cholesterol. We examined in vitro the effects on HDL receptor [scavenger receptor class B type I (SR-BI)] activity of three classes of clinical and experimental plasma HDL-cholesterol-elevating compounds: niacin, fibrates, and HDL376. Fenofibrate (FF) and HDL376 were potent (IC(50) approximately 1 microM), direct inhibitors of SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI. FF, a prodrug, was a more potent inhibitor of SR-BI than an activator of peroxisome proliferator-activated receptor alpha, a target of its active fenofibric acid (FFA) derivative. Nevertheless, FFA, four other fibrates (clofibrate, gemfibrozil, ciprofibrate, and bezafibrate), and niacin had little, if any, effect on SR-BI, suggesting that they do not directly target SR-BI in vivo. However, similarities of HDL376 treatment and SR-BI gene knockout on HDL metabolism in vivo (increased HDL-cholesterol and HDL particle sizes) and structure-activity relationship analysis suggest that SR-BI may be a target of HDL376 in vivo. HDL376 and other inhibitors may help elucidate SR-BI function in diverse mammalian models and determine the therapeutic potential of SR-BI-directed pharmaceuticals.

    Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Publishing Authors By Initials

    tj nielandTJ Nieland,jt shawJT Shaw,fa jaipuriFA Jaipuri,z maligaZ Maliga,jl duffnerJL Duffner,an koehlerAN Koehler,m kriegerM Krieger,

    For similar thiourea research abstracts see: thiourea research

    PUBMED ID PMID:

    MEDLINE DATE:

    Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: Journal of lipid research

    VOLUME: 48

    Page Numbers: 1832-45

    Journal Abbreviation: J. Lipid Res.

    ISSN: 0022-2275

    DAY: 28

    MONTH: 05

    YEAR: 2007

    Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 376606

    Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Keywords Mesh Terms:

    KEYWORDS: Thiourea

    MESH TERMS: pharmacology

    Chemical & Substance for Abstract: Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. Information

    Substance Name: Clofibric Acid

    Registry Number: 882-09-7

    Grant and Affiliation Information for Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.

    AFFILIATION: Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NCI

    GRANT: N01 CO-12400

    ACRONYM: CO

    MEDLINETA: J Lipid Res

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News